Project title: Next generation animal models to define therapies for NETs
Pawel Mazur, PhD MD Anderson Cancer Center
- Status: Completed
- Year(s): 2018
- Grant Type: Collaborative
- Research Type: Basic
- Primary Tumor Site: Pancreas
- Area of Inquiry: Models
- Article/Video: Click Here
- Also seen in May 2018 eUpdate
General Description
Mazur will explore an enzyme (KMT NSD3 or NSD3) in laboratory models of pNETs with genomic alterations in PTEN, MEN1, and ATRX to see if it helps pancreatic NETs. NSD3 may amplify the impact of these alterations, helping to give neuroendocrine cancer cells the “green light” to reproduce and grow.
MD Anderson Scientist Awarded Research Grant
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells?
Outcomes:
We have developed a mouse model of pancreatic neuroendocrine tumors. We found that NSD3 methyltransferase is important driver of malignant progression. We concluded that targeting NSD3 could be beneficial in treatment of pancreatic neuroendocrine tumors.
Additional Details
- City: Houston
- State: Texas
- Grant Duration: 2 years
- Grant Partner: American Association for Cancer Research (AACR)
- Awards: No information
DISCLAIMER
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.